Harry J M Groen - JoVE Visualize

Showing results (191-200 of 274) with videos related to

Pageof 28

Sort By:

Oncogene|October 12, 2018

Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibitionH Rudolf de Boer, Martin Pool, Esméé Joosten, et al.

Cancer Treatment Reviews|October 5, 2023

A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatmentsFenneke Zwierenga, Bianca A M H van Veggel, Anke van den Berg, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2010

A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancerJoline S W Lind, Anne-Marie C Dingemans, Harry J M Groen, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 12, 2013

PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patientsVikram R Bollineni, Gerald S M A Kerner, Jan Pruim, et al.

The European Respiratory Journal|July 13, 2013

Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trialNanda Horeweg, Carlijn M van der Aalst, Rozemarijn Vliegenthart, et al.

The Lancet. Oncology|June 11, 2016

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trialDavid Planchard, Benjamin Besse, Harry J M Groen, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2005

Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancerRonald Hoekstra, Filip Y F L de Vos, Ferry A L M Eskens, et al.

Thorax|December 29, 2018

Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening studyJoan E Walter, Marjolein A Heuvelmans, Kevin Ten Haaf, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2021

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic AnalysisDavid Planchard, Benjamin Besse, Harry J M Groen, et al.

Genes, Chromosomes & Cancer|September 23, 2015

Identification and validation of WISP1 as an epigenetic regulator of metastasis in oral squamous cell carcinomaMartijn J A M Clausen, Lieuwe J Melchers, Mirjam F Mastik, et al.

Pageof 28

Showing results (191-200 of 274) with videos related to

Sort By:

Pageof 28

Oncogene|October 12, 2018

Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibitionH Rudolf de Boer, Martin Pool, Esméé Joosten, et al.

Cancer Treatment Reviews|October 5, 2023

A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatmentsFenneke Zwierenga, Bianca A M H van Veggel, Anke van den Berg, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2010

A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancerJoline S W Lind, Anne-Marie C Dingemans, Harry J M Groen, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 12, 2013

PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patientsVikram R Bollineni, Gerald S M A Kerner, Jan Pruim, et al.

The European Respiratory Journal|July 13, 2013

Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trialNanda Horeweg, Carlijn M van der Aalst, Rozemarijn Vliegenthart, et al.

The Lancet. Oncology|June 11, 2016

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trialDavid Planchard, Benjamin Besse, Harry J M Groen, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2005

Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancerRonald Hoekstra, Filip Y F L de Vos, Ferry A L M Eskens, et al.

Thorax|December 29, 2018

Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening studyJoan E Walter, Marjolein A Heuvelmans, Kevin Ten Haaf, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2021

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic AnalysisDavid Planchard, Benjamin Besse, Harry J M Groen, et al.

Genes, Chromosomes & Cancer|September 23, 2015

Identification and validation of WISP1 as an epigenetic regulator of metastasis in oral squamous cell carcinomaMartijn J A M Clausen, Lieuwe J Melchers, Mirjam F Mastik, et al.

Pageof 28